Please assess the completion status of the following clinical trial:

Trial Title: Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18 to 70 years~* NAFLD, defined by confirmed hepatic steatosis by imaging or by liver biopsy, in the absence of other causes of hepatic steatosis or significant alcohol consumption. If liver imaging or biopsy has not been performed clinically, liver ultrasound assessment will be performed as part of the screening visit.~* Early-stage liver fibrosis, defined as fibrosis less than or equal to Fibrosis Stage 3 (F3), confirmed by either (1) a recent liver biopsy or (2) a recent elastography / Fibroscan study. If no recent biopsy or elastography/Fibroscan have been performed, a Fibroscan will be performed as part of the screening visit.~Exclusion Criteria:~* Liver fibrosis stage \> 3~* Current aspirin use~* Contraindications to aspirin use~* Contraindications to magnetic resonance imaging (MRI)~* Pregnancy or desire to become pregnant~* Breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: EXPERIMENTAL): Low-dose (81mg) aspirin tablets
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).